Co-expression of immune checkpoints, such as PD-L1 and TIM-3/TIGIT, has been correlated with poor overall survival in several cancer types, including esophageal squamous cell carcinoma, underscoring the potential of combination therapies targeting these checkpoints to enhance clinical outcomes (61). The gene discussed is HAVCR2; the disease is cancer.